A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Public ClinicalTrials.gov record NCT06999187. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/1b, Multicenter, Open-label, Dose Escalation/Expansion, Multiple-dose Study to Evaluate the Safety and Activity of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas
Study identification
- NCT ID
- NCT06999187
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Dren Bio
- Industry
- Enrollment
- 96 participants
Conditions and interventions
Conditions
- Castrate Resistant Prostate Cancer
- Cervical Cancer
- Endometrial Cancer
- Gastric Cancer
- Gastroesophageal-junction Cancer
- HER2-negative Breast Cancer
- Head-and-neck Squamous Cell Carcinoma
- Non Small Cell Lung Cancer
- Ovarian Cancer
- Pancreatic Ductal Adenocarcinoma
- Triple Negative Breast Cancer
- Urothelial Carcinoma
Interventions
- DR-0202 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 2, 2025
- Primary completion
- Jun 30, 2027
- Completion
- Nov 30, 2027
- Last update posted
- Jan 6, 2026
2025 – 2027
United States locations
- U.S. sites
- 10
- U.S. states
- 7
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Dren Investigational Site | Denver | Colorado | 80218 | Recruiting |
| Dren Investigational Site | Orlando | Florida | 32827 | Recruiting |
| Dren Investigational Site | Sarasota | Florida | 34232 | Recruiting |
| Dren Investigational Site | Huntersville | North Carolina | 28078 | Recruiting |
| Dren Investigational Site | Oklahoma City | Oklahoma | 73104 | Recruiting |
| Dren Investigational Site | Greenville | South Carolina | 29605 | Recruiting |
| Dren Investigational Site | Austin | Texas | 78758 | Recruiting |
| Dren Investigational Site | Dallas | Texas | 75230 | Recruiting |
| Dren Investigational Site | San Antonio | Texas | 78229 | Recruiting |
| Dren Investigational Site | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06999187, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 6, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06999187 live on ClinicalTrials.gov.